CD274 and breast carcinoma: Although preclinical models provide a solid basis that certain low-dose chemotherapies, such as cyclophosphamide or vinorelbine, improve anti-PD-L1 activity in breast cancer, these therapeutic approaches need to be tested in clinical trials.